做為單一療法，適用於帶有 EGFR 突變之局部晚期或轉移性非小細胞肺癌（NSCLC）成人病人的第一線治療。

Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor; Antineoplastic Agent, Tyrosine Kinase Inhibitor

Protein binding: ~98%.
Metabolism: hepatic, primarily via oxidation and glutathione conjugation.
Bioavailability: 80%.
Half-life elimination: 70 hours.
Time to peak: ~6 hours.
Excretion: feces (79%); urine(3%).

Hypersensitivity to dacomitinib or any component of the formulation.

X

>10%: skin rash (69% to 78%), paronychia (64%), xeroderma (30%), alopecia (23%), pruritus (21%), hypoalbuminemia (44%), hyperglycemia (36%), hypocalcemia (33%), hypokalemia (29%), hyponatremia (26%), weight loss (26%), hypomagnesemia (22%), diarrhea (87%), stomatitis (45%), decreased appetite (31%), nausea (19%), constipation (13%) , anemia (44%), lymphocytopenia (42%), increased serum alanine aminotransferase (40%), increased serum aspartate aminotransferase (35%), increased serum alkaline phosphatase (22%), increased creatinine clearance (24%), cough (21%), nasal signs and symptoms (19%).

Non–small cell lung cancer, metastatic, first-line (EGFR exon 19 deletion- or exon 21 L858R substitution mutation-positive):
45 mg once daily until disease progression or unacceptable toxicity.

---

Suggested dose adjustments for Vizimpro adverse reactions

Dose level	once a day
recommended initial dose	45mg
first dose reduction	30 mg
second dose reduction	15mg

No dosage adjustment is necessary.